Viking Therapeutics Climbs After Fatty Liver Disease Results

Mar 27 2019, 11:57 AMMar 27 2019, 2:32 PMMarch 27 2019, 11:57 AMMarch 27 2019, 2:32 PM

(Bloomberg) -- Viking Therapeutics jumped 14 percent pre-market Wednesday after an abstract of its experimental fatty liver disease drug, VK2809 was released ahead of the International Liver Congress Annual Meeting of the European Association for the Study of the Liver (EASL) next month.

Story Link: Viking Therapeutics Climbs After Fatty Liver Disease Results